Latest Posts

All Posts

Comparing Cas9 to NgAgo: Can the Argonautes Best CRISPR?

Posted by Mary Gearing on Jun 9, 2016 10:30:00 AM

THE ORIGINAL NgAgo ARTICLE DISCUSSED IN THIS POST HAS BEEN RETRACTED AND FOLLOW UP STUDIES HAVE FAILED TO REPEAT THE RESULTS DISCUSSED BELOW

Biologists are going gaga over the newest gene-editing protein - a DNA-cleaving Argonaute from Natronobacterium gregoryi, or NgAgo for short. Addgene has already distributed this plasmid all over the world, and the question on everyone’s minds is: could NgAgo replace CRISPR? Such a drastic shift won’t happen overnight, but there are a few reasons why you might choose NgAgo over CRISPR proteins Cas9 or Cpf1 - keep reading to learn more!

Read More >

Topics: Plasmid Technology, Genome Engineering, CRISPR

Searchable and Sortable gRNAs for Your Next CRISPR Experiment

Posted by Nicole Waxmonsky on May 17, 2016 10:30:00 AM

This post was written jointly by Addgenies Brook Pyhtila and Nicole Waxmonsky


Resource sharing shortens the time needed to go from planning an experiment to performing one.  At Addgene, over 120 labs have deposited CRISPR reagents, including many gRNA-containing plasmids (McDade et al, 2016). Many of the gRNAs contained within these plasmids have been used successfully in peer reviewed articles. If you’re targeting your favorite gene with CRISPR, using one of these validated gRNAs can save you the time that would be spent making and testing entirely new gRNA designs. You can now easily find many validated gRNAs in our newly curated Validated gRNA Target Sequence Table.

Read More >

Topics: Genome Engineering, Inside Addgene, CRISPR

Targeting HIV-1 with CRISPR: Shock and Kill or Cut it Out?

Posted by Mary Gearing on May 10, 2016 10:30:00 AM


Over 25 million people worldwide are currently infected with the
lentivirus HIV-1. Today, HIV-1 can be controlled with antiviral therapies such that the virus is undetectable in the blood. But the virus doesn’t completely disappear; it just hides in latently infected cells. To truly cure HIV-1, researchers need to vanquish these hidden viral reservoirs, and CRISPR may be the way to accomplish this tough job! Kamel Khalili’s lab at Temple University has demonstrated two potential strategies for CRISPR-HIV therapeutics - one using dCas9-SAM to activate HIV-1 transcription and destroy infected cells, the other using wild-type Cas9 to remove the HIV-1 genome from infected cells. Read on to learn how CRISPR can take on HIV-1 in vitro, and what obstacles must be overcome for clinical success.

Read More >

Topics: Genome Engineering, CRISPR

CRISPR Antimicrobials

Posted by Mary Gearing on May 3, 2016 10:30:00 AM

The crisis of antibiotic resistance is upon us, and the world is unprepared. Each year in the United States, two million people will be infected by antibiotic resistant bacteria. Even when researchers develop new antibiotics, the onset of resistance is swift, as few as five years after introduction. Current antibiotic strategies are nonspecific - they harm any bacterial cell without a resistance gene, allowing resistant bacteria to multiply, spreading their resistance genes throughout the bacterial population. But what if we could specifically target only virulent or antibiotic resistant bacteria with a weapon that they’ll have less potential to become resistant to? CRISPR may provide a method for doing just that. While challenges remain in the delivery of these agents, CRISPR antimicrobials could become our newest line of defense against bacteria.

Read More >

Topics: Genome Engineering, CRISPR

Casilio: An Adaptive, Multitasking “CRISPR-OS”

Posted by Guest Blogger on Apr 26, 2016 10:30:00 AM

This post was contributed by guest bloggers Albert Cheng and Mark Wanner.

CRISPR-Cas9 offers a leap forward for genome editing, providing researchers with greatly enhanced accuracy, efficiency, and versatility. It has led to a tremendous acceleration of biomedical research, allowing for the modeling of human disease mutations in experimental model systems with previously unthinkable speed and precision. Furthermore, the ability to excise detrimental mutations and introduce functional sequences—as is being investigated with dystrophin/Duchenne muscular dystrophy at this time—is potentially transformative for human clinical care for some Mendelian diseases.

Read More >

Topics: Plasmid Technology, Genome Engineering, CRISPR

Blog Logo Vertical-01.png

Subscribe to Our Blog